reports
Centene Corp: 1 director
Two Directors at Centene Corp bought 19,512 shares at between 0.000USD and 25.500USD. The significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
- Jonathan Moreland
TNDM TANDEM DIABETES CARE INC
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
GOGO GOGO INC.
CNC CENTENE CORPORATION
CHD CHURCH & DWIGHT CO. INC.
ASA ASA
SAFT SAFETY INSURANCE GROUP INC.
GBLI GLOBAL INDEMNITY PLC
AMBC AMBAC FINANCIAL GROUP INC.
BL BLACKLINE INC.
ICHR ICHOR HOLDINGS LTD.
SONO SONOS
ESTA ESTABLISHMENT LABS HOLDINGS
PINE ALPINE INCOME PROPERTY TRUST
FOUR SHIFT4 PAYMENTS
DLHC INC.
ENVX DALEIGH HOLDINGS CORP
PTLO ENOVIX CORP
BRCC PORTILLOS INC
CSR BRC INC
SMRT INVESTORS REAL ESTATE TRUST
LNW SMARTRENT INC
BOOM LIGHT & WONDER INC.
DYNAMIC MATERIALS CORPORATION
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annua...
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at 11:30 am ET. The live webcast of the fireside chat may be a...
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and ...
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE™-1 Phase 1b Trial of TN-401 Enrolled and First PKP2-associated ARVC Patient Dosed in Cohort 2 Following DSMB Recommendation to Dose Escalate and Expand Data Readouts from Both TN-201 and TN-401 Clinical Programs Planned for the Fourth Quarter of 2025 Cash Runway into Second Half of 2026 SO...
- Jonathan Moreland
ANTM ANTHEM INC.
SSB SOUTH STATE CORPORATION
SNV SYNOVUS FINANCIAL CORP.
SIGI SELECTIVE INSURANCE GROUP INC.
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
RLI RLI CORP.
PSX PHILLIPS 66
PRGS PROGRESS SOFTWARE CORPORATION
PNFP PINNACLE FINANCIAL PARTNERS INC.
NVCR NOVOCURE LTD.
MTH MERITAGE HOMES CORPORATION
MSCI MSCI INC. CLASS A
MOFG MIDWESTONE FINANCIAL GROUP
FBIZ FIRST BUSINESS FINANCIAL SERVICES
CNC CENTENE CORPORATION
CHTR CHARTER COMMUNICATIONS INC. CLASS A
ALGN ALIGN TECHNOLOGY INC.
UPS UNITED PARCEL SERVICE INC. CLASS B
PETS PETMED EXPRESS INC.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
PBT PERMIAN BASIN ROYALTY TRUST
LIND LINDBLAD EXPEDITIONS HOLDINGS
KYN KAYNE ANDERSON MLP INVESTMENT CO.
PLBC PLUMAS BANCORP
CZWI CITIZENS COMMUNITY BANCORP
MBIN MERCHANTS BANCORP
PGC PEAPACK-GLADSTONE FINANCIAL CORP.
LOOP LOOP INDUSTRIES
CHMG CHEMUNG FINANCIAL CORP.
FVCB FVCBANKCORP
TLRY TILRAY
TROX TRONOX HOLDINGS PLC
AMTB AMERANT BANCORP (A)
PCB PACIFIC CITY FINANCIAL CORP
DMAC DIAMEDICA THERAPEUTICS INC.
CRDF CARDIFF ONCOLOGY INC
ABSI ABSCI CORP
NSPR INSPIREMD INC
BRCC BRC INC
JMSB JOHN MARSHALL BANCORP INC
PRME PRIME MEDICINE INC
MMC MARSH & MCLENNAN COMPANIES INC.
STRW STRAWBERRY FIELDS REIT INC.
AURX NUO THERAPEUTICS
DMA INC.
MRAI DESTRA MULTI ALTERNATIVE FUND
GF MARPAI
CVM INC.
THE NEW GERMANY FUND
INC.
CEL-SCI CORPORATION
Tenaya Receives Positive Safety Reviews from Independent DSMBs to Adva...
Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2 Expected in Fourth Quarter of 2025 First Patient Dosed in 6E13 vg/kg Cohort 2 of RIDGE™-1 Phase 1b Clinical Trial of TN-401 for Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Initial Cohort 1 Data for TN-401 and Enrollment of Additional Patients in Bo...
- Jonathan Moreland
SIGI SELECTIVE INSURANCE GROUP INC.
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
MTH MERITAGE HOMES CORPORATION
MOFG MIDWESTONE FINANCIAL GROUP
CNC CENTENE CORPORATION
BUSE FIRST BUSEY CORPORATION
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
SONO SONOS
PCB PACIFIC CITY FINANCIAL CORP
ABSI ABSCI CORP
NEGG NEWEGG COMMERCE INC.
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rul...
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 461,000 shares of Tenaya common stock to three new non-executive employees in connection with the commencement of their employment. The stock options have an exerci...
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and ...
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will present five abstracts at the upcoming American Society ...
Tenaya Therapeutics Reports First Quarter 2025 Financial Results and P...
Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Interim Data from Low Dose Cohort in MyPEAKTM-1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification RIDGE Natural History and Seroprevalence Study Highlights Significant Disease Burden and Unmet Need Among Adults with PKP2-associated ARVC Data Readouts for TN-201 and TN-401 Clinical Programs On Track for the Second Half of 2025 Cash Runway Extended into Second Half of 2026 SOUTH SAN FRANCISCO, Calif., ...
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History ...
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025 RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene Patients Experience High Burden of Arrhythmias and Severe Disease Progression Despite Standard-of-Care Treatments Large Majority of PKP2-associated ARVC Patients Appear Eligible for TN-401 Gene Therapy Based on Low Rates of Preexisting Immunity to AAV9 Antib...
- Dave Nicoski
- Ross LaDuke
BKD BROOKDALE SENIOR LIVING INC.
STRL STERLING CONSTRUCTION COMPANY INC.
SLP SIMULATIONS PLUS
MKTX MARKETAXESS HOLDINGS INC.
MDLZ MONDELEZ INTERNATIONAL INC. CLASS A
HII HUMANA INC.
HCA HUNTINGTON INGALLS INDUSTRIES INC.
GD HCA HEALTHCARE INC
DLTR GENERAL DYNAMICS CORPORATION
DG DOLLAR TREE INC.
CVGW DOLLAR GENERAL CORPORATION
CNC CALAVO GROWERS INC.
CL CENTENE CORPORATION
CACI COLGATE-PALMOLIVE COMPANY
FDP CACI INTERNATIONAL INC CLASS A
SJW FRESH DEL MONTE PRODUCE INC.
LKO SJW GROUP
FIZZ LAKES OIL N.L.
CELH NATIONAL BEVERAGE CORP.
PAGS CELSIUS HOLDINGS INC.
STNE PAGSEGURO DIGITAL LTD
LHX STONECO
CERT L3HARRIS TECHNOLOGIES INC
MASS CERTARA
CTGO 908 DEVICES
NTST CONTANGO ORE INC.
YOU NETSTREIT CORP
HUM CLEAR SECURE INC
HAMILTON U.S. MID-CAP FINANCIALS ETF
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of NextEra Energy, Inc., Florida Power & Light Company, NextEra Energy Capital Holdings, Inc. and other ratings that are associated with these issuers. The review was conducted through a rating committee held on 26 March 2025 ...
Tenaya Therapeutics Announces Late Breaker Presentation of New Data fr...
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with Severe Disease at Baseline Achieved NYHA Class I Two of Three Patients Experienced Improvements in One or More Measures of Hypertrophy Expects to Complete Enrollment of Cohort 2 in 1H25 and to Report Initial Data in 2H25 ...
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 En...
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models Robust Evidence of Disease Reversal in Severe Knock Out Mice Model Supports Tenaya’s Clinical Development Plan to Evaluate TN-201 as a Potential Treatment for Patients with MYBPC3-associated Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that addres...
Tenaya Therapeutics Announces Late Breaker and New Data Presentations ...
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that new clinical and disease burden data pert...
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financia...
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data Accepted for Late-Breaker Presentation at the American College of Cardiology Meeting Initial Data from RIDGE™-1 Phase 1b Clinical Trial of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Expected in 2H25 Recent $48.9 Million Financing Extends Cash Runway into mid-2026 SOUTH SAN FR...
- Jonathan Moreland
PEB PEBBLEBROOK HOTEL TRUST
PBF PBF ENERGY INC. CLASS A
MTDR MATADOR RESOURCES COMPANY
MPC MARATHON PETROLEUM CORPORATION
LTRX LANTRONIX INC.
FRPT FRESHPET INC
EIX EDISON INTERNATIONAL
DRTTF DIRTT ENVIRONMENTAL SOLUTIONS
CMCO COLUMBUS MCKINNON CORPORATION
FLWS 1-800-FLOWERS.COM CL A
JELD JELD-WEN HOLDING INC.
FRAF FRANKLIN FINANCIAL SERVICES CO.
ELAN ELANCO ANIMAL HEALTH INC.
ABCL ABCELLERA BIOLOGICS
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
JANX JANUX THERAPEUTICS INC
TNYA TENAYA THERAPEUTICS INC
IE IVANHOE ELECTRIC INC
ECAT BLACKROCK ESG CAP ALLOCATION TR
ELTX ANGION BIOMEDICA CORP
CVI CVR ENERGY
GAM INC.
GENERAL DE ALQUILER DE MAQUINARIA
Tenaya Therapeutics Announces Pricing of Public Offering
Tenaya Therapeutics Announces Pricing of Public Offering SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 75,000,000 total units for gross proceeds of approximately $52.5 million prior to deducting underwriting discounts and commissions and offering expenses. Tenaya intends to use the net procee...
Tenaya Therapeutics Announces Proposed Public Offering
Tenaya Therapeutics Announces Proposed Public Offering SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and Series A warrants and Series B warrants, each to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded units consisting of pr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.